Editas gets approval for CRISPR study on patients with a rare disorder

Editas gets approval for CRISPR study on patients with a rare disorder

FDA signs off on Editas CRISPR study on patients with a rare genetic disorder

By DAMIAN GARDE

RUBY WALLAU FOR STAT

The news may reassure a biotech industry trying to piece together what the Chinese experiment might mean for its more staid ambitions in CRISPR.

READ MORE